In September 2022, deucravacitinib (Sotyktu), a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, was approved by the FDA. Aside from its first-in-class mechanism of action, it is the first approved de novo deuterated drug.
This premium deep dive into deucravacitinib includes:
- the industry context
- the clinical data
- the target rationale
- the mechanism of action
- the drug’s origins
See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.